"Sodium_Stibogluconate"^^ . "16037-91-5"^^ . "MyostibinFBNCI" . "LenoctaBRNCI" . "C0003383"^^ . . . "PentostamFBNCI" . "Pharmacologic Substance"^^ . "12001-86-4"^^ . "VQD001CNNCI" . "Chemical Viewed Functionally"^^ . "sodium stibogluconatePTNCI-GLOSSCDR0000482341" . "V083S0159D"^^ . "Sodium StibogluconatePTNCI" . . "FDA"^^ . "Sodium StibogluconatePTDCP50554" . "475763"^^ . . "SSGPTNCI-GLOSSCDR0000523297" . "SODIUM STIBOGLUCONATEPTFDAV083S0159D" . "SSGABNCI" . . "Antimony Sodium GluconateSYNCI" . "SolustinFBNCI" . "C61083"^^ . "Sodium Stibogluconate"^^ . "Organic Chemical"^^ . "A substance being studied in the treatment of certain solid tumors, lymphoma, and myeloma. Sodium stibogluconate may block enzymes needed for cancer growth. It is a type of pentavalent antimonial.NCI-GLOSS" . "SolustibosanFBNCI" . "475763"^^ . "Sodium Stibogluconate"^^ . "Pentavalent antimony (Sb) in differential complex formation with gluconic acid with leishmanicidal and potential antineoplastic activities. The Sb moiety of sodium stibogluconate (SSG) may inhibit protein tyrosine phosphorylases (PTPases) by covalently modifying sulfhydryl groups in PTPase cysteine residues, resulting in specific inactivation of SH2 domain-containing tyrosine phosphatases-1 and -2 (SHP-1 and SHP-2), PTPases which negatively regulate interferon (IFN) signaling; enhancement of IFN-induced Stat1 tyrosine phosphorylation; and induction of cellular protein tyrosine phosphorylation. SSG in combination with IFN-alpha may synergize to overcome tumor cell resistance to IFN-alpha-mediated apoptosis.NCI" . "C12H18O17Sb2.2Na"^^ . "CHEBI:28148"^^ . .